RemSleep Holdings (RMSL) Free Cash Flow Growth (3y) (2013 - 2025)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 6.28% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 9.63% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 22.80% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 29.36% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | -27.72% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | -0.27% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 77.20% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | -20.37% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 19.32% |
| 10 | RemSleep Holdings | - | - | -7,636.00 | 26.21% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 26.21% |
| Sep 30, 2025 | 18.19% |
| Jun 30, 2025 | 55.35% |
| Mar 31, 2025 | 21.08% |
| Dec 31, 2024 | -21.52% |
| Sep 30, 2024 | -47.52% |
| Jun 30, 2024 | -2.25% |
| Mar 31, 2024 | -11.95% |
| Dec 31, 2023 | -44.22% |
| Sep 30, 2023 | -52.60% |
| Jun 30, 2023 | -20.10% |
| Mar 31, 2023 | -47.40% |
| Dec 31, 2022 | -35.92% |
| Sep 30, 2022 | -47.62% |
| Jun 30, 2022 | -199.97% |
| Mar 31, 2022 | -49.89% |
| Dec 31, 2021 | -41.01% |
| Sep 30, 2021 | -24.36% |
| Jun 30, 2021 | -56.52% |
| Mar 31, 2021 | -43.71% |
| Dec 31, 2020 | -39.33% |
| Sep 30, 2020 | -31.33% |
| Jun 30, 2020 | -79.00% |
| Mar 31, 2020 | -63.60% |
| Dec 31, 2019 | -6.22% |
| Sep 30, 2019 | -193.13% |
| Jun 30, 2019 | -167.94% |
| Mar 31, 2019 | -36.71% |
| Dec 31, 2018 | -43.75% |
| Jun 30, 2018 | 1.16% |
| Mar 31, 2018 | -4.91% |
| Dec 31, 2017 | 34.97% |
| Dec 31, 2016 | -249.51% |
| Sep 30, 2016 | 40.03% |
| Jun 30, 2016 | 84.82% |
| Mar 31, 2016 | -392.22% |
| Dec 31, 2015 | 40.78% |
| Jun 30, 2015 | 86.64% |
| Mar 31, 2015 | -11.01% |
| Dec 31, 2014 | -9.16% |
| Dec 31, 2013 | 76.27% |
| Sep 30, 2013 | 77.05% |